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Evidence Based Summary

Can routine screening and iron supplementation for iron
deficiency anemia in nonsymptomatic pregnant women
improve maternal and infant health outcomes?
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C linical S cenario
Pregnant women have an increased need for iron that might not be met with diet alone. Due to physiologic anemia and population
differences, no set criteria for defining iron deficiency anemia (IDA) are available globally. Serum ferritin and transferrin levels
are often used to guide therapy by clinicians. Studies have reported an association between poor iron status and negative health
outcomes such as low birth weight, premature birth, and perinatal death for women and their infants, although the evidence is weak.
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Background
Prenatal screening for IDA and routine iron supplementation
may allow clinicians to diagnose and preemptively treat iron
deficiency and IDA in pregnant women, leading to a decreased
risk of future negative health outcomes. However, there is a lack
of one consistent set of guidelines that can be applied safely to
all populations globally. These guidelines will let clinicians deliver
the most efficient care to their patients. One such effort was made
by the United States Preventive Services Task Force (USPSTF),
which last reviewed evidence on prenatal screening for IDA
in 2006 and recommended routine screening on the basis
of fair‑quality evidence. According to the USPTF, although
there is insufficient evidence for screening asymptomatic or
treating nonanemic asymptomatic pregnant women, treatment
of asymptomatic IDA has moderate health benefits. This
summary reports the evidence for routine screening and iron
supplementation for IDA in nonsymptomatic pregnant women.

How was the Study Done?
Researchers from the USPSTF conducted a systematic review
and meta‑analysis of studies reporting routine screening and
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iron supplementation for asymptomatic (anemic and nonanemic)
women and the intervention’s effect on any health outcomes for
women and infants.
The review included randomized controlled trials, nonrandomized,
controlled trials and cohort studies including asymptomatic
pregnant women receiving screening or supplementation for
IDA, and the studies were in English. When good‑ and fair‑quality
studies were available, poor‑quality studies were excluded as were
studies only published with abstracts or without original data.
The review focused on studies using iron supplementation and
treatment regimens commonly used in clinical practice in the
United States and those conducted in countries with “high” or
“very high” human development based on the United Nations’s
Human Development Index.

How was Quality of Evidence Assessed?
Study quality was assessed by the two reviewers who used
predefined criteria set by the USPSTF, which rates study
quality as good, fair, or poor. Discrepancies were addressed by
consensus.
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Table 1: Summary of pooled results
Intervention
Routine iron supplementation versus
no supplementation or placebo

Outcome
Preterm delivery (defined as
delivery at <37 weeks)
Low birth weight (defined mostly
as <2500 g)
IDA (defined as hemoglobin level
<110 g/L and serum ferritin level
<27 pmol/L or <44.9 pmol/L)
Iron deficiency (defined as
serum ferritin level <27 pmol/L,
<33.7 pmol/L, or <44.9 pmol/L)

Effect estimate
#
RR 0.88 (95% *CI: 0.55, 1.42)
Two studies, n=1,010
RR 1.10 (95% CI: 0.54, 2.25)
Three studies, n=688

Heterogeneity

Quality

χ² P 0.38; I I 0%

Fair

χ² P 0.45; I I2 0%

Fair

RR 0.29 (95% CI: 0.17, 0.49)
Four studies, n=762

χ² P 0.55; I I2 0%

Fair

RR 0.53 (95% CI: 0.33, 0.84)
Three studies, n=510

χ² P 0.20; I I2 40%

Fair

2

*CI: Confidence interval; #RR: Risk ratio

What did the Study Find?
After conducting a thorough search, researchers from the USPSTF
selected 12 trials that compared the effects of routine prenatal iron
supplementation versus no supplementation. No trials reporting on
the benefits or harm of routine screening on pregnant, maternal,
or infant health outcomes were found. Evidence from new trials
supports the previous findings of routine supplementation
improving maternal IDA and other blood indices. However,
there is still insubstantial evidence for the effect of routine
iron supplementation or screening on maternal or infant health
outcomes as reported in Table 1. This means that the current
evidence supports the previous USPTF recommendations of
routine prenatal iron supplementation. Studies included were of
good and fair quality; however, due to low number of trials, there is
a lack of generalizability, no consistent amount of iron dose used,
and clinical outcomes mostly reported as ad hoc events.

Implications for Clinical Practice
Evidence supports routine supplementation in terms of maternal
hematologic health but does not have any impact on maternal and
infant clinical health outcomes. For the second question, evidence
was not strong enough to support or oppose the effect of routine
screening on anemic and nonanemic women in terms of future
health benefit(s) or harm(s) for the involved woman or infant. For
physicians, the message is that routine supplementation of iron
during pregnancy does improve hematologic markers in women
reducing future risk of IDA, so it should be continued. However,
routine screening for IDA in asymptomatic women may or may
not be conducted since there is still a lack of sufficient evidence
to develop a recommendation for this procedure.

screening impacted future clinical outcomes of women and their
children as well as whether routine IDA screening should be
implemented in asymptomatic women. This report, albeit able
to corroborate the findings for routine iron supplementation,
found inadequate evidence for routine IDA screening and
did not address whether routine IDA screening will impact
the hematologic indices of asymptomatic women. These gaps
need to be filled with strong long‑term clinical trials needed to
evaluate the effect of screening and routine iron supplementation
on maternal and infant short‑ and long‑term health outcomes.
Trials need to be conducted on a large scale in high‑, middle‑,
and low‑income countries that focus on certain regimens, stratify
populations based on risk factors, and are powered to report
clinical outcomes.

Conclusion
Trials support the use of routine iron supplementation in anemic
and nonanemic asymptomatic pregnant women; however, there
is a lack of evidence for or against routine screening in this
population.
This evidence-based summary is based on Cantor 2015.[1]
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